title: Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
authors.affiliation: Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Max J
authors.initials: MJ
authors.lastname: Gordon
authors.affiliation: Department of Pathology, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Philipp W
authors.initials: PW
authors.lastname: Raess
authors.affiliation: Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Young
authors.affiliation: Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Stephen E F
authors.initials: SEF
authors.lastname: Spurgeon
authors.affiliation: Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Alexey V
authors.initials: AV
authors.lastname: Danilov
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010880:Piperidines; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: cytogenetics; ibrutinib; prolymphocytic leukaemia